5-HT1A/1B antagonist with roughly equal affinity at each receptor; also a β-adrenoceptor antagonist.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 345.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.9 mL||14.48 mL||28.95 mL|
|5 mM||0.58 mL||2.9 mL||5.79 mL|
|10 mM||0.29 mL||1.45 mL||2.9 mL|
|50 mM||0.06 mL||0.29 mL||0.58 mL|
References are publications that support the biological activity of the product.
Engel et al (1986) Identity of presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn Schmiedebergs Arch.Pharmacol. 332 1 PMID: 2936965
Giles et al (1996) Characterization of a 5-HT1B receptor on CHO cells: functional responses in the absence of radioligand binding. Br.J.Pharmacol. 117 1119 PMID: 8882605
Hoey et al (1996) Atypical responses of rat ileum to pindolol, cyanopindolol and iodocyanopindolol. Br.J.Pharmacol. 117 712 PMID: 8646418
Blue et al (1989) Interaction of dihydroalprenolol and cyanopindolol with atypical β-adrenoceptors in guinea-pig ileum. Br.J.Pharmacol. 96 246P
If you know of a relevant reference for Cyanopindolol hemifumarate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Cyanopindolol hemifumarate, Cyanopindolol hemifumarate supplier, 5-HT1A/1B, antagonists, β-adrenergic, beta-adrenergic, β-adrenoceptor, beta-adrenoceptor, b-adrenergic, b-adrenoceptor, Serotonin, 5-HT1A, Receptors, 5-HT1B, Non-selective, Adrenergic, Beta, 0993, Tocris Bioscience
4 Citations for Cyanopindolol hemifumarate
Citations are publications that use Tocris products. Selected citations for Cyanopindolol hemifumarate include:
Brahmadevara et al (2004) ALpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta. Br J Pharmacol 142 781 PMID: 15205310
Geerts et al (1999) Involvement of 5-HT1B receptors in collar-induced hypersensitivity to 5-hydroxytryptamine of the rabbit carotid artery. Br J Pharmacol 127 1327 PMID: 10455282
Kaya et al (2009) Coupling of β2-adrenoceptors to XLαs and Gαs: a new insight into ligand-induced G protein activation. J Pharmacol Exp Ther 329 350 PMID: 19144685
Gautam et al (2016) Tryptophan hydroxylase 1 and 5-HT7 receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling. Mol Cancer 15 75 PMID: 27871326
Do you know of a great paper that uses Cyanopindolol hemifumarate from Tocris? Please let us know.
Reviews for Cyanopindolol hemifumarate
There are currently no reviews for this product. Be the first to review Cyanopindolol hemifumarate and earn rewards!
Have you used Cyanopindolol hemifumarate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.